Overview

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin